In this issue:
CheckMate 649: exploratory biomarker analyses of efficacy
APOLLO: first-line anlotinib + penpulimab vs. sorafenib in unresectable HCC
Survival outcomes with KRAS variants in BTC
Timing of adjuvant chemotherapy after gastrectomy in gastric cancer
TIMES: sarcopenia & surgical timing in locally advanced oesophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy
JCOG1113: subgroup analysis of intrahepatic cholangiocarcinoma with liver cirrhosis
Organ-specific ORRs with nivolumab + ipilimumab in HCC
ClarIDHy: benefit–risk assessment of ivosidenib vs. placebo in mIDH1 cholangiocarcinomas
Please login below to download this issue (PDF)